Valuation: Genexine, Inc.

Market Cap 243B 169M 147M 137M 126M 237M 16.13B 241M 1.61B 632M 8.03B 635M 621M 26.93B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 171M 149M 138M 127M 240M 16.33B 244M 1.63B 640M 8.13B 642M 628M 27.25B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-15 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
30/09/25 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
22/09/25 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
07/03/25 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
30/09/24 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
04/07/24 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
25/06/24 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
14/05/24 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/11/23 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23/10/23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
31/08/23 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day+5.34%
1 week-0.40%
1 month-2.38%
3 months-54.60%
6 months-51.09%
Current year-47.39%
1 week 2,220
Extreme 2220
2,535
1 month 2,140
Extreme 2140
2,550
Current year 2,140
Extreme 2140
7,490
1 year 2,140
Extreme 2140
7,490
3 years 2,140
Extreme 2140
12,300
5 years 2,140
Extreme 2140
73,692.31
10 years 2,140
Extreme 2140
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 25/03/2025
Chief Executive Officer 61 26/01/2023
Corporate Officer/Principal 49 31/12/2021
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 28/03/2022
Director/Board Member 61 26/01/2023
Date Insider Type Main position Quantity % Market Cap.
22/10/24 Others 156,632 0.3773%
22/10/24 Others

Chief Executive Officer

1,691,165 4.0741%
22/10/24 Others 563,723 1.3580%
Change 5-day change 1-year change 3-year change Capi.($)
+5.34%-0.40%-52.32%-74.59% 78M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average +0.42%-3.31%+25.80%+134.16% 23.39B
Weighted average by Cap. +0.23%-2.96%+28.64%+119.92%

Financials

2022 2023
Net sales 16.14B 11.23M 9.76M 9.09M 8.34M 15.75M 1.07B 16M 107M 42.03M 534M 42.17M 41.24M 1.79B 4.43B 3.08M 2.68M 2.49M 2.29M 4.32M 294M 4.39M 29.37M 11.53M 146M 11.57M 11.31M 491M
Net income -55.97B -38.94M -33.85M -31.51M -28.93M -54.63M -3.72B -55.48M -371M -146M -1.85B -146M -143M -6.21B -66.87B -46.53M -40.44M -37.65M -34.56M -65.27M -4.44B -66.28M -444M -174M -2.21B -175M -171M -7.41B
Net Debt 62.14B 43.23M 37.58M 34.98M 32.12M 60.65M 4.13B 61.59M 412M 162M 2.05B 162M 159M 6.89B 2.94B 2.05M 1.78M 1.66M 1.52M 2.87M 196M 2.92M 19.54M 7.67M 97.37M 7.69M 7.53M 327M
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
31/07/26 ₩2,465.00 +5.34% 103,150
30/07/26 ₩2,340.00 -0.21% 119,286
29/07/26 ₩2,345.00 -0.21% 155,300
28/07/26 ₩2,350.00 -3.69% 101,287
27/07/26 ₩2,440.00 -1.41% 58,762
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock